Research Use Only · Not for Human Consumption · For Licensed Practitioners Only · Must be 21+ · Verify Local Laws
Licensed Practitioners Only

Peptide supply your
practice can stand behind.

US 503(b) contract manufactured. cGMP. ISO. Identity, purity, stability, and heavy metals tested on every batch. Full documentation formatted for clinic compliance records — available to approved practitioner accounts.

Apply for a Practitioner Account →

No minimum order. Wholesale pricing. COA pack included with every order.

🏭
Manufacturer
US-registered 503(b) outsourcing facility
Not imported API. Domestic manufacturing under FDA oversight.
🧪
Manufacturing Standard
cGMP · ISO certified
Current Good Manufacturing Practice. ISO quality management.
📋
Testing
Independent third-party — every batch
Identity · Purity · Stability · Heavy metals. Batch-specific COAs.
📄
Documentation
Clinic-ready compliance pack
Formatted for board review, malpractice documentation, and clinic records.
US 503(b) Manufactured
cGMP · ISO
LC-MS Identity Confirmed
RP-HPLC Purity Verified
ICP-MS Metals Panel
No Minimum Order
Why practitioners choose Revia Well

Three problems every practitioner
faces right now.

The gray market is consolidating. The compounding pharmacy pathway is 12–18 months away. Your patients need access now — with documentation you can defend.

01
Supply chain uncertainty
Peptide Sciences shut down in March 2026. Warning letters hit a dozen more vendors. The gray market suppliers your patients relied on are disappearing. A reliable, quality-documented source isn't optional — it's urgent.
→ Revia Well is a US-sourced, fully documented supply chain that's still standing.
02
Defensibility
If your state board, malpractice carrier, or a patient attorney asked today to document your peptide supplier — the manufacturer, the testing methodology, the batch records — what would you hand them? Most practitioners have no answer.
→ Every Revia Well order includes a clinic-ready compliance documentation pack.
03
The transition
503A compounding pharmacy access is real — but rulemaking takes 12–18 months after PCAC votes. The realistic earliest date for pharmacy access is late 2027. Until then, your only quality-documented option is the RUO channel.
→ We'll help you transition when compounding opens. You won't need to walk away from a gray market vendor.
Testing protocol

What we test on every batch.

Independent third-party laboratory testing on every production batch — not sampled, not estimated. Batch-specific certificates of analysis available for your clinic records.

Method: RP-HPLC
Purity
≥98% minimum — confirmed
Reverse-phase high-performance liquid chromatography. Gold standard for peptide purity quantification. Distinguishes the target compound from synthesis byproducts and degradation products.
Method: LC-MS
Identity
Compound confirmed — every batch
Liquid chromatography–mass spectrometry confirms molecular identity at the sequence level. Verifies the exact compound — not just a purity percentage — before the batch ships.
Method: ICP-MS
Heavy Metals
<50 ppb — all metals
Inductively coupled plasma–mass spectrometry. Tests for lead, arsenic, mercury, and cadmium. Most gray market vendors never run this panel. It is non-negotiable for any injectable-grade compound.
Documented
Stability
Degradation profile on file
Stability data documents compound integrity over time and temperature exposure. Essential for clinic storage protocols and patient counseling on shelf life.
ℹ️
On our COA documentation: Testing is conducted by Chromate Independent Laboratory (chromate.org/verify), a third-party analytical laboratory independent of Revia LLC and our manufacturing partner. Every COA includes a batch number, access code, and independent verification link. Batch-specific COAs are provided with every practitioner order and are formatted for clinic compliance files.
Regulatory context

The honest timeline to
503A compounding access.

The regulatory picture is moving — but slower than the headlines suggest. Here's what's actually happening and what it means for your practice.

Apr 22, 2026
12 peptides removed from FDA Category 2 Complete
Including BPC-157, TB-500, GHK-Cu, Semax, Epitalon, KPV, MOTS-C, LL-37, and more. Removal from Category 2 does not authorize compounding — it removes the prohibition.
Jul 23–24, 2026
PCAC advisory committee hearing — 7 peptides Upcoming
BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, Emideltide under review for 503A Bulk Drug Substances List. Committee vote is non-binding. Formal rulemaking must follow.
Before Feb 2027
Second PCAC hearing — 5 additional peptides Scheduled
GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II. Same process as July hearing.
Late 2027 est.
Earliest realistic 503A compounding pharmacy access Estimated
Notice-and-comment rulemaking typically takes 12–18 months after a favorable PCAC vote. Based on historical FDA rulemaking timelines, late 2027 is the optimistic estimate.
Revia LLC on the federal record
Revia LLC submitted formal public comments to the FDA's Pharmacy Compounding Advisory Committee on June 10, 2026, in support of 503A inclusion for all 12 peptides under review. Comment tracking number: mq8-c88x-9wb1. Docket: FDA-2025-N-6895. View on regulations.gov →
Practitioner account benefits

What every practitioner
account includes.

Approved accounts receive wholesale pricing, full documentation, and ongoing regulatory support — with no minimum order requirement to get started.

💲
Wholesale pricing
Per-unit wholesale pricing exclusive to approved practitioner accounts. Pricing provided upon account approval. No minimum order — trial orders welcome.
📁
Compliance documentation pack
Batch-specific COAs for every compound ordered, manufacturer credentials, testing methodology documentation, and regulatory status summary — formatted for clinic files.
🔄
Autoship available
Set recurring orders for your most-used compounds. Predictable supply for active clinic accounts with no disruption to patient protocols.
📰
Regulatory briefings
Direct updates on PCAC hearing outcomes, rulemaking timelines, and what each regulatory development means for your practice — before it hits the general media.
📚
Protocol resources
Access to clinical protocol resources via Peptide Protocol Portal and Integrative Practice Solutions to support your patient programs.
🔁
Transition support
When 503A compounding pharmacy access opens, we'll help you transition. You won't need to quietly walk away from a gray market vendor — we're already building toward that standard.
Available compounds

Compounds available to
practitioner accounts.

The following compounds are available to approved accounts. All are tested to the standards above. Full catalog provided upon account approval.

Compound Category Purity (RP-HPLC) Metals (ICP-MS) Regulatory Status
BPC-157Healing & Recovery99.19%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
TB-500Healing & Recovery98.85%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
SemaxCognitive98.92%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
SelankCognitive≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026
EpitalonLongevity≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
GHK-CuLongevity≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Feb 2027
SS-31 (Elamipretide)Longevity≥98%Conforms <50ppbRUO — available
KPVHealing & Recovery≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
MOTS-CLongevity≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
IpamorelinGrowth Hormone99.28%Conforms <50ppbRUO — available
SermorelinGrowth Hormone≥98%Conforms <50ppbRUO — available
TesamorelinGrowth Hormone≥98%Conforms <50ppbRUO — available
LL-37Immune≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Feb 2027
DihexaCognitive≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Feb 2027
Emideltide (DSIP)Cognitive≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Jul 2026
PEG-MGFHealing & Recovery≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Feb 2027
Melanotan IILongevity≥98%Conforms <50ppbRemoved from Cat. 2 Apr 2026 · PCAC Feb 2027
NAD+Longevity≥98%Conforms <50ppbRUO — available

Purity figures reflect batch H.012526 testing results where available. All other compounds tested to ≥98% minimum threshold. Full COA documentation available upon account approval. Additional compounds available — full catalog provided to approved accounts.

On the federal record
We submitted formal FDA public comments.
Revia LLC submitted written comments to the FDA's Pharmacy Compounding Advisory Committee on June 10, 2026, in support of 503A inclusion for BPC-157, TB-500, Semax, Epitalon, KPV, MOTS-C, Emideltide, and the five compounds scheduled for February 2027 review. We argued that quality-documented US suppliers deserve a regulated pathway — and that the gray market restriction created the unsafe supply chain it was meant to prevent.
Tracking: mq8-c88x-9wb1 · Docket: FDA-2025-N-6895 · Document: FDA-2025-N-6895-0001
📜
Federal record
Practitioner account application

Apply for a practitioner account.

Accounts are approved for licensed practitioners. No minimum order. Wholesale pricing and full documentation pack provided upon approval. Typical response within one business day.

By submitting this form you confirm you are a licensed healthcare practitioner. All compounds are supplied for research use only. Revia LLC verifies practitioner credentials before account approval. Your information is never shared or sold.

✅
Application received.
Thank you. We review practitioner applications within one business day. You'll receive a confirmation at the email you provided, followed by your account approval and wholesale pricing details. If you have urgent supply needs, email orders@revialife.com directly.